ArticleJournal of radiation research2025
Tumor shrinkage after simultaneous proton therapy for multiple hepatocellular carcinomas.
Article in Journal of radiation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are no reports on shrinkage of multiple hepatocellular carcinomas (HCCs) after simultaneous treatment with radiotherapy. The purpose of the study was to examine the relationship between tumor shrinkage and treatment outcomes for several HCCs irradiated simultaneously using proton beam therapy (PBT). The subjects were 46 patients with multiple HCCs (95 lesions) who received PBT between January 2008 and December 2018. Overall survival (OS), local control (LC) and complete+partial response (CR + PR) rates were determined using the Kaplan-Meier method. The median follow-up period was 29.2 months and the 3-year OS was 50.3%. For the 95 lesions, the 3-year LC rate was 90.4% and the CR + PR rate was 85.2% at 3 years. Three combination protocols (referred to as A, B and C) were used for different lesions in the same patient: A (66 Gray (Gy) Relative biological effectiveness (RBE) in 10 fractions (fr))-B (72.6 Gy(RBE) in 22 fr) (22 lesions), A-C (74 Gy(RBE) in 37 fr) (15 lesions) and B-C (2 lesions). The 1-year CR + PR rates were 75.8% for A and 56.4% for B in A-B cases (P = 0.14), and 62.5% for A and 57.1% for C in A-C cases (P = 0.35). In the B-C group, there was only one patient with 2 lesions. The lesion treated with the B protocol reached CR + PR, while that treated with the C protocol did not reach CR + PR. These results show that some cases can have differences in tumor shrinkage after concurrent PBT for multiple HCCs, and that there is no significant relationship between dose and tumor shrinkage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.